Biohaven Ltd. Stock 12‑Month Price Target Raised to $25, Implies 65% Upside

What happened

Estimates from 13 analysts show Biohaven Ltd.'s average price target rising from $24.85 to $25, with forecasts ranging from $9 to $48 per share. Based on the Nov. 2 closing price, the new target implies about 65% potential upside.

Confirmed

Global impact / market context

A higher average target suggests analysts expect more value from Biohaven shares. Because the average hides a wide $9 to $48 range, investors face real disagreement about the company's prospects, and the 65% implied upside reflects analyst expectations, not a guarantee.

Analyst inference

The consensus rating stays at "Buy" across 15 covering analysts, split into 10 Buys, 4 Holds and 1 Sell. That majority support, combined with the raised target, signals generally positive analyst views, while the single Sell shows not everyone agrees on the outlook.

Analyst inference

What to watch

1. The analyst count and rating split: 15 analysts cover Biohaven, with 10 Buys, 4 Holds and 1 Sell. Watch whether these ratings shift after new company or industry information emerges. Confirmed
2. Watch whether more analysts raise their price targets toward the $48 high end or cut toward the $9 low end, since movement in either direction would show how expectations for Biohaven are changing. Proposed
3. Watch whether Biohaven's actual results and news move the stock toward the $25 average target. Reaching the implied 65% upside depends on future performance meeting analyst expectations. Analyst inference

Evidence

• Original source link unavailable